Placeholder

Ketoprofen

  • # LGM Pharma is a Ketoprofen CAS# 22071-15-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Ketoprofen
  • CAS #: 22071-15-4
  • Mode of Action:

    The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.

  • Pharmacodynamics:

    Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.

  • Metabolism:

    Rapidly and extensively metabolized in the liver, primarily via conjugation to glucuronic acid. No active metabolites have been identified.

  • Toxicity:

    LD50=62.4 mg/kg (rat, oral).Symptoms of overdose include drowsiness, vomiting and abdominal pain.Side effects are usually mild and mainly involved the GI tract. Most common adverse GI effect is dyspepsia (11% of patients). May cause nausea, diarrhea, abdominal pain, constipation and flatulence in greater than 3% of patients.

  • IUPAC: 2-(3-benzoylphenyl)propanoic acid
  • ATC: M01AE03 M01AE17 M02AA10
  • PubChem: 3825
  • DrugBank: DB01009 (APRD01059, DB05823)
  • Formula: C16H14F3N3O2S
  • Molecular Mass: 254.2806
  • Synonyms: m-Benzoylhydratropic acid
  • SMILES: CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
  • AHFS Code: 28:08.04.92
  • InChl: DKYWVDODHFEZIM-UHFFFAOYSA-N
  • General Reference:

    1. Kantor TG: Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy. 1986 May-Jun;6(3):93-103. Pubmed
    2. Mazieres B: Topical ketoprofen patch. Drugs R D. 2005;6(6):337-44. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements